Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 April 2020Website:
http://zentalis.comNext earnings report:
27 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 15 Nov 2024 21:32:27 GMTDividend
Analysts recommendations
Institutional Ownership
ZNTL Latest News
FMR LLC (Trades, Portfolio), a prominent investment firm, recently adjusted its holdings in Zentalis Pharmaceuticals Inc (ZNTL, Financial), a clinical-stage biopharmaceutical company. On September 30, 2024, FMR LLC (Trades, Portfolio) reduced its position by 3,600,886 shares, resulting in a new total of 5,075,837 shares.
ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.
NEW YORK , Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) breached their fiduciary duties to shareholders.
Monday, the FDA lifted the partial clinical hold on studies of Zentalis Pharmaceuticals, Inc.'s ZNTL azenosertib, the company's novel, selective, and orally bioavailable inhibitor of WEE1.
Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024 Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024
The recent regulatory setbacks related to Zentalis' (ZNTL) lead pipeline candidate, azenosertib, weigh heavily on the stock.
NEW YORK CITY, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL.
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ: ZNTL ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK CITY, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL.
What type of business is Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
What sector is Zentalis Pharmaceuticals in?
Zentalis Pharmaceuticals is in the Healthcare sector
What industry is Zentalis Pharmaceuticals in?
Zentalis Pharmaceuticals is in the Biotechnology industry
What country is Zentalis Pharmaceuticals from?
Zentalis Pharmaceuticals is headquartered in United States
When did Zentalis Pharmaceuticals go public?
Zentalis Pharmaceuticals initial public offering (IPO) was on 03 April 2020
What is Zentalis Pharmaceuticals website?
https://zentalis.com
Is Zentalis Pharmaceuticals in the S&P 500?
No, Zentalis Pharmaceuticals is not included in the S&P 500 index
Is Zentalis Pharmaceuticals in the NASDAQ 100?
No, Zentalis Pharmaceuticals is not included in the NASDAQ 100 index
Is Zentalis Pharmaceuticals in the Dow Jones?
No, Zentalis Pharmaceuticals is not included in the Dow Jones index
When was Zentalis Pharmaceuticals the previous earnings report?
No data
When does Zentalis Pharmaceuticals earnings report?
The next expected earnings date for Zentalis Pharmaceuticals is 27 February 2025